Prior Dengue Virus Infection May Cause Severe Outcomes Following Zika Virus Infection During Pregnancy, Mount Sinai Study Shows
Women who have previously been infected with dengue virus may be at risk for increased damage to their fetuses and placentas if they should later become infected with the Zika virus, researchers from the Department of Microbiology at the Icahn School of Medicine at Mount Sinai report.
This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.
Results of the study, “Dengue virus immunity increases Zika virus-induced damage during pregnancy,” were published in the February issue of Immunity, a journal published by Cell Press.
Zika virus outbreaks were first found to be associated with birth defects including microcephaly, in which the baby is born with an abnormally small head and brain, in 2015 in Brazil, where dengue virus, a virus closely related to Zika virus, is endemic. The research team led by Jean Lim, PhD, Associate Professor of Microbiology and Co-Director of Microbiology Multidisciplinary Training in the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, transferred dengue virus-specific antibodies into mice prior to infection with Zika virus during pregnancy. The presence of these antibodies in the mice significantly increased placental damage, fetal growth, and fetal resorption. Zika-infected human placental tissues also showed increased replication in the presence of dengue antibodies.
“Our data demonstrate that antibodies generated from a previous dengue virus infection can enhance the severity of Zika virus infection during pregnancy,” said Dr. Lim. “Our research may explain the high rate of microcephaly and birth defects observed in the recent Zika virus outbreak in South America.”
Other key authors on the study include Florian Krammer, PhD, Associate Professor of Microbiology, and Adolfo Garcia-Sastre, PhD, Director of Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.
